Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-7423
- Development stage
- Preclinical
- Lead developer
- Assembly Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABI-7423 is an investigational, oral, broad-spectrum non-nucleoside polymerase inhibitor being developed for the treatment of transplant-associated herpesviruses. It is designed to inhibit viral DNA polymerase activity, thereby blocking replication of a range of herpesviruses that can cause significant morbidity in immunocompromised patients, such as those undergoing organ transplantation. The drug is currently in IND/CTA-enabling studies and has not yet entered clinical trials. Assembly Biosciences is advancing this candidate as part of its antiviral pipeline targeting serious viral diseases[1][6][8].
- Other names
- broad-spectrum non-nucleoside polymerase inhibitorunnamed broad-spectrum polymerase inhibitor
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on ABI-7423.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-7423.